GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACONW) » Definitions » ROCE %

Aclarion (Aclarion) ROCE % : -928.76% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aclarion's annualized ROCE % for the quarter that ended in Mar. 2024 was -928.76%.


Aclarion ROCE % Historical Data

The historical data trend for Aclarion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion ROCE % Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
- - - - -574.50

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -282.18 -998.77 - - -928.76

Aclarion ROCE % Calculation

Aclarion's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-4.303/( ( (2.915 - 0.689) + (2.46 - 3.188) )/ 2 )
=-4.303/( (2.226+-0.728)/ 2 )
=-4.303/0.749
=-574.50 %

Aclarion's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-8.252/( ( (2.46 - 3.188) + (3.727 - 1.222) )/ 2 )
=-8.252/( ( -0.728 + 2.505 )/ 2 )
=-8.252/0.8885
=-928.76 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aclarion  (NAS:ACONW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Aclarion ROCE % Related Terms

Thank you for viewing the detailed overview of Aclarion's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclarion (Aclarion) Business Description

Traded in Other Exchanges
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Aclarion (Aclarion) Headlines

From GuruFocus

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

By Stock market mentor Stock market mentor 01-17-2023

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

By Stock market mentor Stock market mentor 01-31-2023